Research Article

Perbedaan atherogenic index of plasma, ox-LDL dan troponin I pada pasien penyakit jantung koroner stabil dan sindrom koroner akut

Eti Dwi Purwati , Purwanto Adhipireno, Muji Rahayu

Eti Dwi Purwati
Program Pendidikan Dokter Spesialis Patologi Klinik, Fakultas Kedokteran, Universitas Diponegoro/RSUP dr. Kariadi, Semarang, Indonesia. Email: etisofi86@gmail.com

Purwanto Adhipireno
Bagian Patologi Klinik, Fakultas Kedokteran, Universitas Diponegoro, Semarang, Indonesia

Muji Rahayu
Bagian Patologi Klinik, Fakultas Kedokteran, Universitas Diponegoro, Semarang, Indonesia
Online First: December 01, 2020 | Cite this Article
Purwati, E., Adhipireno, P., Rahayu, M. 2020. Perbedaan atherogenic index of plasma, ox-LDL dan troponin I pada pasien penyakit jantung koroner stabil dan sindrom koroner akut. Intisari Sains Medis 11(3): 1152-1156. DOI:10.15562/ism.v11i3.615


Background: Coronary heart disease (CHD) is caused by atherosclerosis in the coronary arteries. Lipid lipoprotein abnormalities as the pathogenesis basic of atherosclerosis can be assessed using atherogenic index of plasma (AIP) and oxidized low density lipoprotein level (ox-LDL). Troponin I has a role in heart muscle damage due to ischemia in CHD. This study aimed to determine the differences of AIP, ox-LDL and troponin I levels in patients with stabel CHD and acute coronary syndrome (ACS).

Methods: This is an observational analytic study with cross-sectional including 34 stable CHD patients and 34 ACS patients from January to March 2019 at Kariadi hospital Semarang. Measurement of triglycerides (TG) and HDL using automatic chemistry, AIP is calculated from log TG/HDL, ox-LDL levels using the ELISA method, troponin I using the ELFA method. AIP statistical analysis used independent t-test while ox-LDL and troponin I levels statistical analysis was using Mann whitney U test. Significant difference was determiner when p < 0.05.

Results: Mean ± SD of AIP in stable CHD was 0.52 ±  0.25 and ACS was 0.55 ± 0.23 with  p = 0.622. Median (min-max) of ox-LDL in stable CHD was 324.74 pg/ml (67.44 – 891.98) and ACS was 717.18 pg/ml (87.35 – 1959.4) with p £ 0.001 and median (min – max) troponin I in stable CHD was 0.026 ug/L (0.018 – 0.035) and ACS was 1.5 ug/L (0.003 – 40) with p £ 0.001.

Conclusion: There were significant differences in ox-LDL and troponin I levels between stable CHD and ACS. There was no significant differences ofAIP show in stable CHD patients and ACS.

 

Pendahuluan: Penyakit jantung koroner (PJK) disebabkan aterosklerosis pada arteri koroner. Kelainan lipid lipoprotein yang menjadi dasar patogenesis aterosklerosis dapat dinilai dengan atherogenic index of plasma (AIP), oxidized low density lipoprotein (ox-LDL). Troponin I berperan pada kerusakan otot jantung akibat iskemia pada PJK. Tujuan dari penelitian ini adalah untuk membuktikan perbedaan nilai AIP, kadar ox-LDL dan troponin I pada pasien PJK stabil dan sindrom koroner akut (SKA).

Metode: Penelitian observasional analitik dengan pendekatan potong lintang dilakukan pada 34 pasien PJK stabil dan 34 pasien SKA di RSUP Dr. Kariadi Semarang. Penetapan trigliserida (TG) dan HDL menggunakan kimia otomatik, AIP dihitung dari log TG/HDL, kadar ox-LDL menggunakan metode ELISA, troponin I mengunakan metode ELFA. Analisis statistik AIP menggunakan independent t-test sedangkan kadar ox-LDL dan troponin I menggunakan Mann whitney U test. Perbedaan bermakna apabila p < 0.05.

Hasil: Rerata ± SD nilai AIP PJK stabil adalah 0.52 ± 0.25 dan SKA 0.55 ± 0.23 dengan p = 0.622. Median (min – maks) ox-LDL PJK stabil 324.74 (67.44 – 891.98) pg/ml dan SKA 717.18 (87.35 – 1959.4) pg/ml dengan nilai p £ 0.001, dan median (min – maks) troponin I PJK stabil 0.026 (0.018 – 0.035) ug/L dan SKA 1.5 (0.003 – 40) ug/L dengan nilai p £ 0.001.

Simpulan: Terdapat perbedaan bermakna kadar ox-LDL dan troponin I dan perbedaan tidak bermakna nilai AIP pada pasien PJK stabil dan SKA.

References

Alwan A. Global status report on non communicable diseases 2010. World Health Organization. 2011.

Mackay J, Mensah GA, Greenlund K. The atlas of heart disease and stroke. World Health Organization. 2004.

Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee G, et al. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease. Med J Islam Repub Iran. 2015; 29: 240.

Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995; 333(20): 1301 – 1307. DOI: 10.1056/NEJM199511163332001.

Itabe H, Obama T, Kato R. The Dynamics of Oxidized LDL during Atherogenesis. J Lipids. 2011; (2090-3030): 418313. DOI: 10.1155/2011/418313.

Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011; 13(6): 544 – 552. DOI: 10.1007/s11886-011-0220-3.

Kumar A, Cannon CP. Acute coronary syndromes: diagnosis and management, part I. Mayo Clin. Proc. 2009; 84(10): 917 – 38.

Dobiasova M, Frohlich J, Sedova M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011; 52(3): 566 – 571. DOI: 10.1194/jlr.P011668

Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013; 34(38): 2949 – 3003. DOI: 10.1093/eurheartj/eht296.

Dai X, Busby-Whitehead J, Forman DE, Alexander KP. Stable ischemic heart disease in the older adults. J Geriatr Cardiol. 2016; 13(2): 109 – 14. DOI: 10.11909/j.issn.1671-5411.2016.02.013.

Fihn SD, Blankenship JC, Alexander KP, Bittl JA, Byrne JG, Fletcher BJ, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2014; 64(18): 1929 – 49. DOI: 10.1016/j.jacc.2014.07.017.

Artha IMJR, Bhargah A, Dharmawan NK, Pande UW, Triyana KA, Mahariski PA, et al. High level of individual lipid profile and lipid ratio as a predictive marker of poor glycemic control in type-2 diabetes mellitus. Vasc Health Risk Manag. 2019; 15: 149 – 157. DOI: 10.2147/VHRM.S209830.

Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Pedoman tatalaksana sindrom koroner akut. Jakarta. 2015

Sharma SB, Garg S. Small dense LDL: risk factor for coronary artery disease (CAD) and its therapeutic modulation. Indian J Biochem Biophys. 2012; 49(2): 77 – 85.

Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009; 2(5-6): 231 – 7. DOI: 10.1242/dmm.001180

Sharma A, Chomayil Y, Karim FA, Parambil VP. Incidence and risk factors of acute coronary syndrome in younger age groups. Int J Emerg Med. 2015; 8(Suppl 1): P4. DOI: 10.1186/1865-1380-8-S1-P4.

Rizzo M, Berneis K, Koulouris S, Pastromas S, Rini GB, Sakellariou D, et al. Should we measure routinely oxidized and atherogenic dense low-density lipoproteins in subjects with type 2 diabetes?. Int J Clin Pract. 2010; 64(12): 1632 – 42.

Tsimikas S, Aikawa M, Miller Jr FJ, Miller ER, Torzewski M, Lentz SR. Increased plasma oxidized phospholipid: apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscler Thromb Vasc Biol. 2007; 27(1): 175 – 81.

Hamm CW, Falk E, Heeschen C, Fox KAA. Acute coronary syndromes: Pathopysiology, diagnosis, and risk stratification. 2020. Diunduh dari : https://www.researchgate.net/publication/265352198.

Adamson PD, Hunter A, Madsen DM, Shah ASV, McAllister DA, Pawade TA, et al. High-sensitivity cardiac troponin I and the diagnosis of coronary artery disease in patients with suspected angina pectoris. Circ Cardiovasc Qual Outcomes. 2018; 11(2): e004227.

Daubert MA, Jeremias A. The utility of troponin measurement to detect myocardial infarction: review of the current findings. Vasc Health Risk Manag. 2010; 6: 691 – 699. DOI: 10.2147/vhrm.s5306.

Lim W, Qushmaq I, Cook DJ, Crowther MA, Heels-Ansdell D, Devereaux PJ. Elevated troponin and myocardial infarction in the intensive care unit: a prospective study. Crit Care. 2005; 9(6): R636 – R644. DOI: 10.1186/cc3816.

Lippi G, Cervellin G. Degradation of troponin I in serum or plasma: mechanisms, and analytical and clinical implications. Semin Thromb Hemost. 2012; 38(2): 222 – 229. DOI: 10.1055/s-0032-1301419.

Danek J, Hnatek T, Maly M, Taborsky M, Belacek J, Skvaril J, et al. Troponin levels in patients with stable CAD. Cor et Vasa. 2017; 59(3): e229 – e234. DOI: 10.1016/j.crvasa. 2016.12.001.

Dokainish H, Pillai M, Murphy SA, DiBattiste PM, Schweiger MJ, Lotfi A. Prognostic implications of elevated troponin in patients with suspected acute coronary syndrome but no critical epicardial coronary disease: A TACTICS-TIMI-18 substudy. J Am Coll Cardiol. 2005; 45(1): 19 – 24. DOI: 10.1016/j.jacc.2004.09.056.


No Supplementary Material available for this article.
Article Views      : 23
PDF Downloads : 10